Lansoprazole Tablet, Orally Disintegrating, Delayed Release
Product Images NDC 0378-6982

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 0378-6982). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lansoprazole Delayed-release Orally Disintegrating Tablets 15 mg Bottle Label (Image 01)

Packaging label for Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg by Mylan Pharmaceuticals Inc. The label shows a package containing 100 unit-dose tablets (10 cards x 10 tablets). It includes NDC 0378-6981-88, pharmacist instructions for preparing the orally disintegrating tablets for patients who have difficulty swallowing, and a barcode.*

FDA Label Image

Lansoprazole Delayed-release Orally Disintegrating Tablets 30 mg Bottle Label (Image 02)

The image shows packaging for Lansoprazole 30 mg delayed-release orally disintegrating tablets by Mylan Pharmaceuticals Inc. The label highlights 100 unit-dose tablets (10 cards x 10 tablets) and includes dosage form and strength. Manufacturer details and pharmacist instructions are also visible, with the Mylan logo.*

FDA Label Image

Lansoprazole Structural Formula (Image 03)

Chemical structure diagram of the active ingredient lansoprazole, showing its molecular components and bonds as represented in the product data for the drug Lansoprazole.*

FDA Label Image

Figure 1. (Image 04)

A line graph titled 'Mean Severity of Day Heartburn By Study Day For Evaluable Patients' displaying three groups: placebo, lansoprazole 15 mg QD, and lansoprazole 30 mg QD. The y-axis shows mean severity levels from 0 (None) to 3 (Severe), and the x-axis shows days from start of treatment, ranging approximately from -5 to 60 days. The graph illustrates a decline in heartburn severity over time for the lansoprazole groups compared to the placebo group.*

FDA Label Image

Figure 2. (Image 05)

A line graph showing mean severity of night heartburn over 60 days of treatment with Lansoprazole 15 mg QD, Lansoprazole 30 mg QD, and placebo. The y-axis represents severity from 0 (none) to 3 (severe), and the x-axis shows days from treatment start. Lansoprazole groups show reduced severity compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.